Session

Back to Programme Overview

Novel methods to improve detection and outcomes of prostate cancer

Poster Session 26

  • Location:
    Room Stockholm, North Hall (Level 1)
  • Chairs:
     A. Rannikko, Helsinki (FI)
     P. Stattin, Uppsala (SE)
     L-P. Xie, Hangzhou (CN)
  • Aims and objectives of this session

    The aim of this session is to provide an update on novel approach to improve detection and outcomes of prostate cancer.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
344
Repeat prostate-specific antigen tests before prostate biopsy: A decreasing in PSA values is associated with a reduced risk of cancer and particularly high grade cancer

By: De Nunzio C., Lombardo R., Presicce F., Deroma M., Tema G., Cancrini F., Tubaro A.

Institutes: Sant’ Andrea Hospital – Sapienza University, Dept. of Urology, Rome, Italy

345
Atorvastatin before prostatectomy and prostate cancer - a randomized, double-blind, placebo controlled clinical trial

By: Murtola T.1, Riikonen J.1, Syvälä H.2, Tolonen T.3, Koskimäki J.1, Pakarainen T.1, Kaipia A.4, Isotalo T.5, Kujala P.3, Tammela T.1

Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, 4Satakunta Central Hospital, Dept. of Urology, Pori, Finland, 5Päijät-Häme Central Hospital, Dept. of Urology, Lahti, Finland

346
The effect of metformin use and the incidence of prostate cancer in type 2 diabetes mellitus patients: A nationwide population-based study

By: Yun S.J.1, Kim S.Y.2, Park J-H.3, Cho I-C.4, Jeong P.5, Kang H.W.5, Ha Y-S.6, Kim W.T.5, Kim Y-J.5, Lee S.C.5, Kim W-J.5

Institutes: 1Chungbuk National University, Dept. of Urology, Cheongju, South Korea, 2Chungbuk National University Hospital, Office of Public Health, Cheongju, South Korea, 3College of Medicine, Chungbuk National University, Dept. of Preventive Medicine, Cheongju, South Korea, 4National Police Hospital, Dept. of Urology, Seoul, South Korea, 5Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, 6Kyungpook National University Medical Center, Dept. of Urology, Daegu, South Korea

347
An automated-microcapillary electrophoresis-based immunoassay system may improve diagnostic accuracy of prostate cancer and be a good indicator of biopsy Gleason score

By: Ishikawa T.1, Yoneyama T.1, Tobisawa Y.1, Hatakeyama S.1, Kurosawa T.2, Nakamura K.2, Koie T.1, Hashimoto Y.1, Ohyama C.1

Institutes: 1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Wako Pure Chemical Industries, Ltd., Diagnostics Research Laboratories, Amagasaki, Japan

348
Association between single nucleotide polymorphisms, gene expression and prostate cancer risk at the moment of diagnosis

By: Puche Sanz I.1, Robles-Fernández I.2, Pascual-Geler M.1, Martínez-Gonzalez L.2, Lorente J.A.2, Cózar-Olmo J.M.1, Álvarez-Cubero M.J.2

Institutes: 1Complejo Hospitalario Universitario Granada, Dept. of Urology, Granada, Spain, 2Pfizer-University of Granada-Junta De Andalucía Centre For Genomics and Oncological Research (GENYO), Dept. of Genomics, Granada, Spain

349
Clinical usefulness of eight novel monoclonal antibodies against prostate-specific antigen (PSA) to differentiate prostate cancer and benign prostate hyperplasia. Measurement of different PSA molecular forms with specific immunoassays

By: Navarro S.2, Royo M.2, Martos L.2, Vera Donoso C.D.1, Martinez-Sarmiento M.1, Alapont J.M.1, Ramon L.A.2, Oto J.2, España F.2, Medina-Badenes P.2

Institutes: 1La Fe, Universitary and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, 2Insituto De Investigación Sanitaria La Fe, Grupo De Hemostasia, Trombosis, Arteriosclerosis Y Biología Vascular, Valencia, Spain

350
Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 and MRI: The double negative effect

By: Perlis N.1, Al-Kasab T.1, Ahmad A.1, Goldberg E.1, Fadak K.1, Sayyid R.1, Finelli A.1, Kulkarni G.1, Hamilton R.1, Zlotta A.2, Fleshner N.1

Institutes: 1University of Toronto, University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, 2University of Toronto, University Health Network and Sinai Health System, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada

351
Circulating tumor cells as a marker of bone metastases in patients with high-risk prostate cancer

By: Cieślikowski W.A.1, Ida A.1, Hrab M.1, Budna J.2, Świerczewska M.2, Jankowiak A.2, Zabel M.2, Antczak A.1

Institutes: 1Poznań University of Medical Sciences, Dept. of Urology, Poznań, Poland, 2Poznań University of Medical Sciences, Dept. of Histology and Embryology, Poznań, Poland

352
Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting

By: Van Den Eeden S.1, Zhang N.4, Shan J.1, Quesenberry C.1, Han J.2, Tsiatis A.3, Lu R.4, Lawrence J.5, Febbo P.5, Presti J.6

Institutes: 1Kaiser Permanente Northern California, Dept. of Research, Oakland, United States of America, 2Kaiser Oakland Medical Center, Dept. of Pathology, Oakland, United States of America, 3Genomic Health, Dept. of Pathology, Redwood City, United States of America, 4Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, 5Genomic Health, Medical Department, Redwood City, United States of America, 6Kaiser Oakland Medical Center, Dept. of Urology, Oakland, United States of America

353
Serum miRNA-supported transrectal MRI-ultrasound fusion-guided biopsy of the prostate enhances tumor prediction and classification

By: Keck B., Wach S., Pöllmann J., Jansen T., Kahlmeyer A., Taubert H., Wullich B.

Institutes: University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

354
The influence of physical activity on prostate cancer diagnosis: A multicenter biopsy cohort analysis

By: De Nunzio C.1, Cindolo L.2, Sountoulidis P.3, Toutziaris C.4, Gacci M.5, Presicce F.1, Cancrini F.1, Schips L.2, Serni S.5, Tubaro A.1

Institutes: 1Sant’Andrea Hospital – Sapienza University, Dept. of Urology, Rome, Italy, 2Padre Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, 3General Hospital of Veria, Dept. of Urology, Veria, Greece, 4Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, 5Careggi Hospital, Dept. of Urology, Florence, Italy

355
Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men

By: Galustian C.1, Rani A.1, Cahill F.2, Santaolalla A.2, Gillett C.3, Lombardelli C.3, Rosekilly J.3, Sakellariou C.1, George G.2, Papaevangelou E.1, Smith R.4, Smolarek D.4, Van Hemelrijck M.2, Dasgupta P.4

Institutes: 1Kings College London, Innate Immunity, MRC Centre for Transplantation, London, United Kingdom, 2Kings College London, Cancer Epidemiology Group, Division of Cancer Sciences, London, United Kingdom, 3Kings College London, KHP Cancer Biobank, 3rd Floor Bermondsey Wing Guy’s Hospital, London, United Kingdom, 4Kings College London, MRC Centre for Transplantation, and Urology Centre, London, United Kingdom

* 356
Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer

By: Briollais L.2, Ozcelik H.2, Xu J.2, Kwiatkowski M.3, Lalonde E.4, Sendorek D.4, Fleshner N.5, Recker F.3, Kuk C.6, Olkhov-Mitsel E.2, Savas S.7, Hanna S.8, Juvet T.5, Hunter G.4, Friedlander M.2, Li H.2, Chadwick K.5, Prassas I.9, Soosaipillai A.9, Randazzo M.3, Trachtenberg J.5, Toi A.5, Shiah Y-J.4, Fraser M.10, Van Der Kwast T.11, Bristow R.10, Bapat B.2, Diamandis E.9, Boutros P.4, Zlotta A.1

Institutes: 1Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, 2Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, 3Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, 4Ontario Institute For Cancer Research, Informatics & Biocomputing Program, Toronto, Canada, 5Princess Margaret Hospital, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada, 6Mount Sinai Hospital, Dept. of Surgery and Urology, Toronto, Canada, 7Memorial University, Craig L. Dobbin Genetics Research Centre, Discipline of Genetics, Faculty of Medicine, St. John’s, Canada, 8Mount Sinai Hospital, Dept. of Surgery, Urology, Toronto, Canada, 9Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, 10Princess Margaret Hospital, University Health Network, Ontario Cancer Institute, Toronto, Canada, 11Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada

Summary
 A. Rannikko, Helsinki (FI)